iQur Ltd Closes £2.6 Million Investment, Wins Major DoH Award For Healthcare Innovation & Signs Pipeline Agreement On Anti-Fibrosis IP

9 Nov 2005

Signing agreement

Advances announced today by the UK-based Company iQur, reinforce its position as a world leader in the development of new treatments for liver disease. It has been chosen as the 2005 winner of the Medical Futures Department of Health Award for Best National Healthcare Innovation for its Hepatitis C genotyping service, that can revolutionise the cost effectiveness of treatment for Hepatitis C. Previously trading as HepCgen, iQur also announced today the final close of an oversubscribed GBP2.6 million follow-on financing, as well as the signing of a major licensing deal with the University of Southampton for its patent estate in the treatment of liver fibrosis.

Read more


Get in touch today to see how we could help you with your next project!

Contact Us